Synopsis: Shares surged 10% after the company secured a Japanese patent for a novel cancer-treatment compound. The patent covers compounds effective against cancer and cancer stem cells, strengthening its R&D capabilities.
The shares of this company are engaged in the manufacturing of bio-based chemicals, and ethanol are in the spotlight after it rose by 10 per cent in today’s market session following securing a Japanese Patent for a cancer treatment compound.
With a market capitalisation of Rs. 1,547 cr, the shares of Godavari Biorefineries Ltd were trading at Rs. 302.35 per share, jumping 10% in today’s market session, making a high of Rs. 312.40, up from its previous close of Rs. 284.15 per share. The stock has delivered a 10% return over the past year, gained 4% year-to-date, and advanced 12% in the last six months, while recording a 1% decline over the past month.
What’s the News
Godavari Biorefineries Ltd has announced that the Japan Patent Office (JPO) has granted a patent for its invention titled “5-Hydroxy-1,4-Naphthalenedione for Use in the Treatment of Cancer.”
The patent relates to a novel class of compounds that have demonstrated strong inhibitory effects on both cancer cells and cancer stem cells. According to the company, the invention has shown significant efficacy against multiple cancer types, including breast cancer and prostate cancer, highlighting its potential therapeutic applications in oncology.
The patent has been granted under Patent No. 7869786 by the Japan Patent Office and was officially registered on May 26, 2026. The original patent application was filed on October 26, 2021, with the Japanese application number 2023-525533.
The grant strengthens Godavari Biorefineries’ intellectual property portfolio and reinforces its research and development capabilities in the pharmaceutical and biotechnology space, potentially opening new opportunities for cancer treatment innovations.
Godavari Biorefineries Ltd is one of the leading Indian biorefining companies that manufactures ethanol, bio-based chemicals, sugar, and power from renewable agricultural feedstocks, primarily sugarcane. The company focuses on sustainable and environmentally friendly products used across industries such as food, pharmaceuticals, cosmetics, agriculture, and energy, supporting the transition toward a greener and circular economy.
It reported a challenging performance in Q4FY26. Revenue declined 3% YoY to Rs. 564 crore from Rs. 580 crore, while EBITDA fell 23% to Rs. 86.2 crore from Rs. 112 crore. Net profit dropped 26% to Rs. 52.9 crore from Rs. 71.9 crore, and EPS decreased 27% to Rs. 10.33 from Rs. 14.06.
Its bio-based chemicals segment continued its shift toward higher-margin specialty products in FY26. The contribution of Specialty Chemicals & Others increased to 61% of revenue from 58% in FY25, while non-specialty chemicals declined to 39%. Driven by a richer product mix and higher specialty chemical sales, segment revenue grew 6.6% YoY to ₹578 crore.
The company’s ethanol business also delivered strong growth, with 98 million litres of ethanol equivalent sold in FY26. Segment revenue rose 12.6% YoY to ₹658.6 crore, supported by strong operational performance and the availability of B-heavy molasses, despite pricing pressures across the industry.
Within the ethanol segment, the Ethanol Blending Programme (EBP) remained the largest contributor, accounting for 81% of sales, followed by Extra Neutral Alcohol (ENA) at 13% and other products at 6%. The performance reflects the company’s focus on specialty chemicals and renewable fuels, supporting growth across its key business segments.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
